Merck Lowers Price of Isentress Drug for State AIDS Programs

Merck & Co. reduced the price of AIDS drug Isentress for U.S. state programs that provide antiviral medicines to lower-income people who have limited or no insurance.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.